Beta-lactam Antibiotics, Critical Care, Infection, Bacterial, Risk Model, Therapeutic Drug Monitoring
Conditions
Keywords
External validation, Critical care, Risk model, Beta-lactam antibiotics, Therapeutic drug monitoring, infections, bacterial
Brief summary
Intensive care (IC) patients regularly get infections. Sometimes it is even the reason of admission to the intensive care unit. To treat these infections, we give medicines called antibiotics, such as β-lactams antibiotics. Every IC patient receives the same dose of β-lactams antibiotics, while we know this can lead to undertreatment in some IC patients. The BATMAN risk score was created to predict which IC patient is undertreated. This study aims to validate the BATMAN risk score so it can be used in clinical practice.
Detailed description
In order to predict which intensive care unit (ICU) patients are not likely to achieve target attainment of beta-lactam antibiotics, a diagnostic multivariable prediction model was developed using random forest analysis. Gender, age, creatinine, and type of beta-lactam antibiotic were included in the final model and translated into a user-friendly and easy-to-implement risk score. As the name suggests, the beta-lactam target non-attainment (BATMAN) risk score predicts which adult ICU patients fail to achieve target attainment and intents efficient use of TDM of beta-lactam antibiotics. In order to use the BATMAN risk score in as many hospitals as possible in clinical practice, an external validation will be performed by a multicenter prospective observational study. All adult ICU patients admitted to the participating hospitals that are treated with beta-lactam antibiotics will be screened for eligibility. One beta-lactam trough plasma concentration, clinical and non-clinical data will be collected prospectively. To our knowledge, no other beta-lactam target non-attainment risk score for adult ICU patients has yet been developed let alone externally validated. This research is essential because ICU patients are a highly heterogenic group of patients that undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics, such as beta-lactam antibiotics. For the beta-lactams, achievement of an adequate drug level is associated with a higher likelihood of clinical success and a decrease in the potential for antimicrobial resistance. Yet, target attainment remains a challenge with the traditional 'one-dose-fits-all' strategy.
Interventions
None listed
Sponsors
Chantal Kats
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent has been obtained from the patient or their legally authorised representative * Age ≥18 years * Treated with one of the following beta-lactam antibiotics at the ICU with intermitted dosage * Amoxicillin (with or without clavulanic acid) * Cefotaxime * Ceftazidime * Cefuroxime * Flucloxacillin * Meropenem * Piperacillin with tazobactam * Eligible blood material within 36 hours after start of beta-lactam antibiotic to determine target attainment (100%ƒT \> MICECOFF). * Suitable intravenous/intra-arterial access to facilitate sample collection
Exclusion criteria
* Pregnancy * Beta-lactam antibiotic cessation before blood sample collection * Receiving beta-lactam antibiotic only as prophylaxis within the context of Selective Digestive tract Decontamination (SDD) * Patients with renal replacement therapy * Patients with burn injury
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Discrimination | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | The discrimination of the diagnostic risk score will be displayed in the concordance index (c-index), which is identical to the area under the receiver operating curve (AUROC), where the true positive rate (y-axis) will be plotted against the false positive rate (x-axis). |
| Calibration | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | The calibration of the risk score will be assessed with a calibration plot, where the average predicted risk of target non-attainment is compared with the overall event rate of target non-attainment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | Sensitivity is the percentage of true positives. |
| Negative predictive value | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | The ratio of subjects truly diagnosed as negative (target attainment) to all those who had negative test results |
| Misclassification | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | Percentage of observations that were incorrectly predicted (false negatives and false positives) |
| Specificity | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | Specificity is the percentage of true negatives. |
| Positive predictive value | Target attainment prediction based on the BATMAN risk score is calculated with patient data within 36 hours after of start therapy. Target attainment based on serum levels are based are measured within 36 hours after start of therapy. | The ratio of subjects truly diagnosed as positive (target non-attainment) to all those who had positive test results. |
Countries
Netherlands
Contacts
Primary ContactChantal Kats, MSc
Outcome results
None listed